Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2104 - A new biomarker of breast cancer stage and patient response to neoadjuvant chemotherapy: HLA-DR expression in cytotoxic and regulatory T cells

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Diana Saraiva

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

D.P. Saraiva1, A. Jacinto1, S. Braga2, M.G. Cabral1

Author affiliations

  • 1 Cedoc, NOVA Medical School, 1150-082 - Lisbon/PT
  • 2 Instituto Cuf De Oncologia, CUF, Lisbon/PT
More

Resources

Abstract 2104

Background

Neoadjuvant chemotherapy (NACT) is the treatment option for locally advanced breast cancer (BC). However, approximately half of the patients have no response. To promptly direct non-responders to personalized therapies, there is an urgency to find a clinical biomarker that could predict treatment response. Tumor infiltrating lymphocytes, namely CD8+ T cells (CTLs) and regulatory T cells (Tregs) are being appointed as biomarkers of response. Nonetheless, tumor cells can escape the immune system by releasing cytokines or expressing immune checkpoint inhibitors, dampening CTLs and increasing Tregs activation. CTLs and Tregs with HLA-DR, a T cell activation marker, by reflecting the tumor immune status, should be a more reliable biomarker of NACT success.

Methods

Fresh biopsies, surgical specimens and blood were collected from 150 BC patients. Immunophenotype was performed by flow cytometry, ELISA and qRT-PCR. Peripheral blood mononuclear cells (PBMCs) were isolated and cultured under canonical stimuli.

Results

67.3% of BC analysed were ER+, 15.5% HER2+ and 17.2% triple negative. Prior to treatment and independent of BC type, BC with no metastasis in the lymph nodes (53%) have HLA-DRhi CTLs (p = 0.003) and HLA-DRlo Tregs (p = 0.002), although the average percentage of lymphocytes and myelocytes are similar between more or less advanced disease. Biopsies from NACT responders also have HLA-DRhi CTLs (p = 0.0006) and HLA-DRlo Tregs (p = 0.0002). A ROC curve revealed a threshold of HLA-DR in CTLs bellow which patients will not respond to NACT. Moreover, HLA-DR+ CTLs express IFN-g, Granzyme B, Perforin, Eomes and TNF-a, essential for CTLs cytolytic activity. HLA-DR+ CTLs negatively correlate with pro-tumorigenesis molecules, such as TGF-b, PD-L1, IL-6, IL-1b and IL-8 (p < 0.005); while HLA-DR+ Tregs positively correlate with them. HLA-DR expression in tumor T cells correlates with its level in systemic T cells (CTLs: r = 0.58 p = 0.001; Tregs: r = 0.65 p = 0.0002). PBMCs stimulated in vitro from NACT responders reveal higher IFN-g and lower IL-10 (p = 0.04).

Conclusions

We propose HLA-DR levels in T cells as a biomarker of BC stage and response to NACT, with the advantage of being systemically evaluated.

Clinical trial identification

Legal entity responsible for the study

CEDOC, Nova Medical School.

Funding

Fundação para a Ciência e Tecnologia (FCT), iNOVA4Health.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings